Engene Holdings Inc (ENGN) Stock Price, Quote & News

Company Profile

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada.

Industry: Biotechnology

Sector: Healthcare

Phone: 514 332 4888

Website: www.engene.com

Address:

4868 Rue Levy, Suite 220, Montreal, Canada

BullJack Dec. 4 at 11:12 PM

$ENGN On November 11, 2025, PERCEPTIVE ADVISORS LLC (Trades, Portfolio) executed a noteworthy transaction by acquiring an additional 4,673,369 shares of enGene Holdings Inc. This acquisition marks a substantial increase of 222.83% in the firm's holdings of the company, bringing the total to 6,770,605 shares. The transaction was completed at a price of $8.82 per share, impacting 1.18% of the firm's portfolio. This strategic move now positions enGene Holdings Inc. as 9.99% of the firm's total holdings, reflecting a significant commitment to the biotechnology sector. Keeping this on watch once I’m out of iren

0 · Reply

Hognose Dec. 3 at 4:20 PM

$ENGN Looks like exit liquidity hitting sells once or twice a day. Big market sell bars.

0 · Reply

topstockalerts Dec. 2 at 4:32 PM

enGene Holdings announced that the FDA has selected its non-viral gene therapy for bladder cancer to participate in a specialized manufacturing readiness program. The company’s therapy, detalimogene voraplasmid, was chosen for the FDA’s Chemistry, Manufacturing and Controls Development and Readiness Pilot Program (CDRP), which supports companies with accelerated clinical timelines and allows early, structured interaction with regulators on manufacturing strategy. CEO Ron Cooper said commercial-scale production has already begun and expects the CDRP to help ensure readiness for filing and eventual commercialization. The news follows encouraging preliminary data from enGene’s pivotal LEGEND trial, which showed an improved 62% complete response rate at six months in high-risk, BCG-unresponsive bladder cancer patients with carcinoma in situ, along with a favorable safety profile across 125 treated patients. $ENGN

0 · Reply

Hognose Dec. 1 at 5:26 PM

$ENGN couple big volume bars.

0 · Reply

Hognose Dec. 1 at 3:46 PM

$ENGN looks ready. Just needs some volume. Low level volume no selling. $10 + incoming.

0 · Reply

Hognose Nov. 26 at 3:29 PM

$ENGN looks like a good setup.

0 · Reply

billsmall Nov. 22 at 10:52 PM

$ENGN So this was a SPAC. Anybody have any info on past bio's who went the SPAC route? Thx

0 · Reply

_www_larval_com_ Nov. 19 at 4:37 PM

$ENGN has turned 5% higher to -1% (~636Kv) moments ago, follow for more volatility.

0 · Reply

Dnwjskdnej Nov. 19 at 1:49 AM

$ENGN what happened, why a 14% drop?

0 · Reply

Dontlookkid Nov. 18 at 9:03 PM

$ENGN 6.08 area coming fast

0 · Reply

enGene's Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness

Nov 25, 2025, 7:30 AM EST - 9 days ago

enGene to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 13, 2025, 12:27 AM EST - 22 days ago

enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants

Nov 12, 2025, 4:01 PM EST - 22 days ago

enGene Announces Proposed Public Offering of Common Shares

Nov 12, 2025, 9:52 AM EST - 22 days ago

enGene Holdings: Still A Buy After A Massive Surge

Nov 11, 2025, 1:41 PM EST - 23 days ago

enGene Holdings Inc. (ENGN) Discusses Preliminary Data From LEGEND Pivotal Cohort in High-Risk BCG-Unresponsive NMIBC Transcript

Nov 11, 2025, 10:37 AM EST - 23 days ago

EnGene Encouraged By Promising Response Rates In Bladder Cancer Trial

Nov 11, 2025, 7:30 AM EST - 23 days ago

Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months

Nov 10, 2025, 4:05 PM EST - 24 days ago

enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial

Nov 6, 2025, 5:00 PM EST - 4 weeks ago

enGene to Participate in Upcoming Investor Conferences

Nov 4, 2025, 1:35 PM EST - 4 weeks ago

enGene Named a BioSpace 2026 Best Places to Work Winner

Oct 1, 2025, 4:03 PM EDT - 2 months ago

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sep 30, 2025, 7:30 AM EDT - 2 months ago

enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer

Sep 11, 2025, 4:03 PM EDT - 3 months ago

enGene Reports Third Quarter 2025 Financial Results and Provides Business Update

Sep 10, 2025, 5:25 PM EDT - 3 months ago

EnGene Holdings Inc. (ENGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 3, 2025, 7:30 AM EDT - 3 months ago

enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort

Jul 8, 2025, 8:00 AM EDT - 5 months ago

enGene Announces Board and Leadership Appointments to Support Commercial Readiness

Jun 25, 2025, 8:00 AM EDT - 5 months ago

FDA Grants RMAT Designation for enGene's Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer

Jun 18, 2025, 4:16 PM EDT - 6 months ago

enGene Holdings: Looking For An End To The 2025 Decline (Downgrade)

Jun 12, 2025, 8:00 AM EDT - 6 months ago

enGene Reports Second Quarter 2025 Financial Results and Provides Business Update

Jun 4, 2025, 8:30 AM EDT - 6 months ago

enGene Announces the Resignation of its Chief Medical Officer

May 29, 2025, 8:00 AM EDT - 6 months ago

enGene to Present at the Jefferies Global Healthcare Conference

May 28, 2025, 7:30 AM EDT - 6 months ago

enGene Names Amy Pott as Chief Global Commercialization Officer

Apr 1, 2025, 8:00 AM EDT - 8 months ago

enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum

Mar 10, 2025, 4:05 PM EDT - 9 months ago

enGene Reports First Quarter 2025 Financial Results and Provides Business Update

Mar 4, 2025, 8:00 AM EST - 9 months ago

enGene to Participate in the Leerink Partners Global Healthcare Conference

Feb 27, 2025, 4:20 AM EST - 10 months ago

enGene Holdings Inc.: Unknown Company Which Looks Like A Catch

Feb 4, 2025, 8:00 AM EST - 10 months ago

enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 30, 2025, 8:00 AM EST - 11 months ago

enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)

Dec 19, 2024, 4:05 PM EST - 1 year ago

enGene Reports Full Year 2024 Financial Results and Provides a Business Update

Dec 15, 2024, 4:53 AM EST - 1 year ago

enGene Holdings: Compelling Early Data Bode Well For Their Near-Term Outlook

Nov 5, 2024, 8:00 AM EST - 1 year ago

enGene to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Oct 25, 2024, 8:00 AM EDT - 1 year ago

enGene Announces $60 Million Private Placement Financing

Oct 22, 2024, 4:05 PM EDT - 1 year ago

enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Oct 21, 2024, 8:45 AM EDT - 1 year ago

enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer

Sep 26, 2024, 6:30 AM EDT - 1 year ago

Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort

Sep 10, 2024, 4:33 PM EDT - 1 year ago

enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update

Jul 24, 2024, 4:05 PM EDT - 1 year ago

enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Jul 24, 2024, 6:30 AM EDT - 1 year ago

enGene Announces Appointment of Ron Cooper as Chief Executive Officer

Jun 14, 2024, 7:01 AM EDT - 1 year ago

enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update

May 15, 2024, 4:05 PM EDT - 1 year ago

enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

May 2, 2024, 4:05 PM EDT - 1 year ago

enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting

Apr 9, 2024, 8:56 AM EDT - 1 year ago

/C O R R E C T I O N -- enGene Inc./

Apr 9, 2024, 8:00 AM EDT - 1 year ago

enGene Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development

Mar 11, 2024, 5:16 PM EDT - 1 year ago

enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress

Mar 5, 2024, 7:00 AM EST - 1 year ago

enGene To Present at the Leerink Partners Global Biopharma Conference

Feb 15, 2024, 6:30 PM EST - 1 year ago

enGene Holdings: Mid-2024 NMIBC Data Could Lead To EG-70 BLA Filing

Feb 14, 2024, 6:50 AM EST - 1 year ago

enGene Announces Oversubscribed $200 Million Private Placement Financing

Feb 14, 2024, 6:45 AM EST - 1 year ago

enGene Announces Leadership Succession Plan

Jan 30, 2024, 7:00 AM EST - 2 years ago

enGene Appoints Lee Giguere as Chief Legal Officer and Corporate Secretary

BullJack Dec. 4 at 11:12 PM

0 · Reply

Hognose Dec. 3 at 4:20 PM

$ENGN Looks like exit liquidity hitting sells once or twice a day. Big market sell bars.

0 · Reply

topstockalerts Dec. 2 at 4:32 PM

0 · Reply

Hognose Dec. 1 at 5:26 PM

$ENGN couple big volume bars.

0 · Reply

Hognose Dec. 1 at 3:46 PM

$ENGN looks ready. Just needs some volume. Low level volume no selling. $10 + incoming.

0 · Reply

Hognose Nov. 26 at 3:29 PM

$ENGN looks like a good setup.

0 · Reply

billsmall Nov. 22 at 10:52 PM

$ENGN So this was a SPAC. Anybody have any info on past bio's who went the SPAC route? Thx

0 · Reply

_www_larval_com_ Nov. 19 at 4:37 PM

$ENGN has turned 5% higher to -1% (~636Kv) moments ago, follow for more volatility.

0 · Reply

Dnwjskdnej Nov. 19 at 1:49 AM

$ENGN what happened, why a 14% drop?

0 · Reply

Dontlookkid Nov. 18 at 9:03 PM

$ENGN 6.08 area coming fast

0 · Reply

ThatTrendingTrader Nov. 15 at 3:44 AM

$ENGN https://www.tipranks.com/news/company-announcements/engene-holdings-closes-130-million-public-offering?utm_source=robinhood.com&utm_medium=referral

1 · Reply

Dontlookkid Nov. 14 at 2:49 PM

$ENGN just send it we know it’s going up

0 · Reply

AAUS1 Nov. 14 at 1:32 PM

$ENGN waiting for a bigger drop

0 · Reply

stoxrgood Nov. 13 at 8:48 PM

$ENGN how is this dropping??? what about all the $20 and $30 price targets??

0 · Reply

NoTworrieD_ Nov. 13 at 7:30 PM

$ENGN back to $9 then $10

0 · Reply

Dontlookkid Nov. 13 at 12:18 PM

$ENGN save the American people and full of sudden today

0 · Reply

ScottyDoesntKnowMeSon Nov. 13 at 12:16 PM

$ENGN flash crash at 4:01 yesterday trigger any one’s else’s stop loss?

0 · Reply

farDoc Nov. 12 at 11:03 PM

$ENGN🚨 $ENGN Short Squeeze Setup? 🚨 Short volume just spiked way above normal 👀 — heavy pressure building that could blow if this starts moving up! Indicator shows big short activity vs 7-day avg. Could be primed for a squeeze if momentum flips. 🔥 Just a stupid ape 🦍 thinking I might be on to something or just on something- lol… Not financial advice! $AMC fellow Ape here.

0 · Reply

farDoc Nov. 12 at 10:34 PM

$ENGN Could this squeeze? Watching and waiting.

2 · Reply

DonCorleone77 Nov. 12 at 9:08 PM

$ENGN enGene announces common shares offering, no amount given

1 · Reply

anachartanalyst Nov. 12 at 8:02 PM

$ENGN https://anachart.com/wp-content/uploads/ana_temp/1762977726_soc-img.jpg

0 · Reply

nbkihy8 Nov. 12 at 5:39 PM

$ENGN They are coming in now. Will push higher

0 · Reply

Market Cap	507.58M
Revenue (ttm)	0.00
Net Income (ttm)	-55.14M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.09

Volume	190,600
Avg Vol	1,489,984
Day's Range	N/A - N/A
Shares Out	64.58M
Stochastic %K	81%
Beta	-0.28
Analysts	Strong Sell
Price Target	$23.50